| Nov 11 |
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
|
| Nov 11 |
How AbbVie can still benefit from Cerevel acquisition despite emraclidine setback
|
| Nov 11 |
AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint
|
| Nov 11 |
Top Stock Movers Now: Tesla, Robinhood Markets, MicroStrategy, and More
|
| Nov 11 |
AbbVie: Emraclidine's Failure Eliminates An Important Growth Driver
|
| Nov 11 |
Top Midday Stories: Cigna Won't Pursue Combination With Humana; AbbVie Phase 2 Schizophrenia Drug Trials Fail to Meet Primary Endpoints
|
| Nov 11 |
AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials
|
| Nov 11 |
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
|
| Nov 11 |
AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.
|
| Nov 11 |
AbbVie Stock Slides on Schizophrenia Drug Study Failure
|
